» Authors » Eugene Verwiel

Eugene Verwiel

Explore the profile of Eugene Verwiel including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 5
Citations 187
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
de Koning H, Schalkwijk J, Stoffels M, Jongekrijg J, Jacobs J, Verwiel E, et al.
Arthritis Res Ther . 2015 Jul; 17:187. PMID: 26198339
Introduction: Schnitzler's syndrome (SchS) is a disabling autoinflammatory disorder, characterized by a chronic urticarial rash, an M-protein, arthralgia, and other signs of systemic inflammation. Anti-interleukin-1 (IL-1) beta antibodies are highly...
2.
Mekenkamp L, Tol J, Dijkstra J, de Krijger I, Vink-Borger M, van Vliet S, et al.
BMC Cancer . 2012 Jul; 12:292. PMID: 22804917
Background: KRAS mutation is a negative predictive factor for treatment with anti-epidermal growth factor receptor (EGFR) antibodies in metastatic colorectal cancer (mCRC). Novel predictive markers are required to further improve...
3.
Kuiper R, Vreede L, Venkatachalam R, Ricketts C, Kamping E, Verwiel E, et al.
Cancer Genet Cytogenet . 2009 Dec; 195(2):105-11. PMID: 19963109
FBXW7 (alias CDC4) is a p53-dependent tumor suppressor gene that exhibits mutations or deletions in a variety of human tumors. Mutation or deletion of the FBXW7 gene has been associated...
4.
Kuipers R, Joosten H, Verwiel E, Paans S, Akerboom J, van der Oost J, et al.
Proteins . 2009 Mar; 76(3):608-16. PMID: 19274741
Correlated mutation analyses (CMA) on multiple sequence alignments are widely used for the prediction of the function of amino acids. The accuracy of CMA-based predictions is mainly determined by the...
5.
Zeilstra J, Joosten S, Dokter M, Verwiel E, Spaargaren M, Pals S
Cancer Res . 2008 May; 68(10):3655-61. PMID: 18483247
Mutation of the genes encoding the WNT signaling components adenomatous polyposis coli or beta-catenin plays a critical role in the initiation of colorectal cancer. These mutations cause constitutively active beta-catenin/TCF-mediated...